Rosenthal, R;
Cadieux, EL;
Salgado, R;
Bakir, MA;
Moore, DA;
Hiley, CT;
Lund, T;
... TRACERx consortium; + view all
(2019)
Neoantigen-directed immune escape in lung cancer evolution.
Nature
10.1038/s41586-019-1032-7.
(In press).
Preview |
Text
Rosenthal_Swanton_2019_wstihfigs.pdf - Accepted Version Download (3MB) | Preview |
Abstract
The interplay between an evolving cancer and a dynamic immune microenvironment remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopathology-assessed tumour-infiltrating lymphocyte estimates. Immune infiltration varied both between and within tumours, with different mechanisms of neoantigen presentation dysfunction enriched in distinct immune microenvironments. Sparsely infiltrated tumours exhibited a waning of neoantigen editing during tumour evolution, indicative of historical immune editing, or copy-number loss of previously clonal neoantigens. Immune-infiltrated tumour regions exhibited ongoing immunoediting, with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoantigens. We identified promoter hypermethylation of genes that contain neoantigenic mutations as an epigenetic mechanism of immunoediting. Our results suggest that the immune microenvironment exerts a strong selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple routes to immune evasion, which are clinically relevant and forecast poor disease-free survival.
Archive Staff Only
 |
View Item |
